Pharmacokinetics, Safety and Tolerability of BIBW 2992 Administered Orally as 20 mg, 30 mg, 40 mg, and 50 mg Tablets (Final Formulation) to Healthy Male Volunteers in an Open-label, Single Rising Dose, Phase I Trial
Latest Information Update: 28 Jun 2014
At a glance
- Drugs Afatinib (Primary)
- Indications Breast cancer; Colorectal cancer; Glioblastoma; Glioma; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record